drugset / Trial / NCT05016934
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
RandomizedParallel-groupTriple-blindPrevention
Summary
Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with other vaccines \[Corona Vac (Sinovac), ChAdOx1 (AZ 1222, Astra Zeneca) or Ad26.Co2.S (Janssen)\].
Timeline
- Start
- 2021-11-01
- Primary completion
- 2022-03-04
- Completion
- 2022-04-20
Outcome
Outcome not reported
Stopped: “At collaborator's request”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A vaccine composed of a recombinant S1 antigen | Vaccine | 10 ug | — |
| Subject | A vaccine composed of a recombinant S1 antigen | Vaccine | 25 ug | — |
| Subject | A vaccine composed of a recombinant S1 antigen | Vaccine | 50 ug | — |